Development of Fluorescent Lectin Tracers With Dedicated Technology for in Vivo Detection of Esophageal Dysplasia in Barrett Patients

Starting soon · Phase 1

Conditions studied: Barrett's Esophagus With or Without Dysplasia, Barrett Esophagus Adenocarcinoma

In brief

The goal of this clinical trial is to evaluate the feasibility of WGA-800CW with dedicated imaging systems for detection of invisible esophageal dysplasia in patients with Barrett's esophagus. The main questions it aims to answer are: * What is the optimal dose of WGA-800CW that maximizes the tumor-to-background ratio and enables clear visualization of the tumor? * Can fluorescence endoscopy with WGA-800CW in combination with qFME detect dysplastic esophageal lesions? In this non-randomized, non-blinded, prospective, feasibility intervention study, 49 participants with Barrett's esophagus will be included. Patients will undergo the combined procedure (qFME and/or OCT-NIRF and HD-WLE). WGA-800CW will be topically administered via a spray catheter during gastroscopy procedures and fluorescent signal will be assessed with qFME and/or OCT-NIRF.

Key facts

Study ID: NCT07643727
Run by: University Medical Center Groningen
People needed: 49
Starts: 2026-06-01
Expected to finish: 2028-10-31
Last updated by the study team: 2026-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with confirmed Barrett's esophagus, esophageal dysplasia, or superficial esophageal ade-nocarcinoma.
Patients scheduled for gastroscopy procedure within the UMCG.
Able to provide written informed consent.

You may not qualify if…

Known allergy to wheat.
Celiac disease.
Dermatitis herpetiformis.
Pregnancy or breastfeeding.

Where it is running

University Medical Center Groningen — Groningen, Provincie Groningen, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.